Multitargeted drugs: the end of the 'one-target-one-disease' philosophy?

被引：87

作者：

Wermuth, CG ^{[1
]}

机构：

[1] Prestwick Chem, F-67400 Illkirch Graffenstaden, France

来源：

DRUG DISCOVERY TODAY | 2004年 / 9卷 / 19期

关键词：

D O I：

10.1016/S1359-6446(04)03213-1

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：826 / 827

页数：2

共 7 条

[1]

[Anonymous], 2003, PRACTICE MED CHEM

[2]

[Anonymous], 1998, Annu. Rep. Med. Chem

[3] MOLECULAR BASIS FOR DRUG ACTION . INTERACTION OF 1 OR MORE DRUGS WITH DIFFERENT RECEPTORS [J].

ARIENS, EJ ;

SIMONIS, AM .

JOURNAL OF PHARMACY AND PHARMACOLOGY, 1964, 16 (05) :289-&

[4]

ARIENS EJ, 1971, DRUG DESIGN, P1

[5] SYMBIOTIC APPROACH TO DRUG DESIGN - ANTIHYPERTENSIVE BETA-ADRENERGIC BLOCKING-AGENTS [J].

BALDWIN, JJ ;

LUMMA, WC ;

LUNDELL, GF ;

PONTICELLO, GS ;

RAAB, AW ;

ENGELHARDT, EL ;

HIRSCHMANN, R ;

SWEET, CS ;

SCRIABINE, A .

JOURNAL OF MEDICINAL CHEMISTRY, 1979, 22 (11) :1284-1290

[6] Novel phenylpiperazine derivatives as dual cytokine regulators with TNF-α suppressing and IL-10 augmenting activity [J].

Hanano, T ;

Adachi, K ;

Aoki, Y ;

Morimoto, H ;

Naka, Y ;

Hisadome, M ;

Fukuda, T ;

Sumichika, H .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (09) :875-879

[7] From magic bullets to designed multiple ligands [J].

Morphy, R ;

Kay, C ;

Rankovic, Z .

DRUG DISCOVERY TODAY, 2004, 9 (15) :641-651

← 1 →